Do analysts rate XBIT or LPCN?

Lipocine has a consensus price target of $15.00, suggesting a potential upside of 635.29%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is XBIT or LPCN more profitable?

XBiotech has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. XBiotech's return on equity of -26.10% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% Lipocine -571.18% -66.70% -59.39%

Does the media favor CTOR or LPCN?

In the previous week, Citius Oncology and Citius Oncology both had 1 articles in the media. Citius Oncology's average media sentiment score of 0.25 beat Lipocine's score of 0.00 indicating that Citius Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LPCN or PLRX?

In the previous week, Lipocine and Lipocine both had 1 articles in the media. Lipocine's average media sentiment score of 0.00 equaled Pliant Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MCRB or LPCN?

In the previous week, Seres Therapeutics had 3 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for Seres Therapeutics and 1 mentions for Lipocine. Seres Therapeutics' average media sentiment score of 0.81 beat Lipocine's score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lipocine (LPCN) Competitors

$2.04 -0.01 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.14 +0.10 (+4.80%)

As of 07:57 PM Eastern

Compare

LPCN vs. XBIT, CTOR, PLRX, BHST, and MCRB

Should you buy Lipocine stock or one of its competitors? MarketBeat compares Lipocine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lipocine include XBiotech (XBIT), Citius Oncology (CTOR), Pliant Therapeutics (PLRX), BioHarvest Sciences (BHST), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

How does Lipocine compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

XBiotech has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

Lipocine has higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Lipocine	$1.98M	8.49	-$9.63M	-$1.88	N/A

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 6.4% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lipocine had 1 more articles in the media than XBiotech. MarketBeat recorded 1 mentions for Lipocine and 0 mentions for XBiotech. XBiotech's average media sentiment score of 0.00 equaled Lipocine'saverage media sentiment score.

Company	Overall Sentiment
XBiotech	Neutral
Lipocine	Neutral

XBiotech has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. XBiotech's return on equity of -26.10% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Lipocine	-571.18%	-66.70%	-59.39%

Lipocine has a consensus price target of $15.00, suggesting a potential upside of 635.29%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

XBiotech and Lipocine tied by winning 7 of the 14 factors compared between the two stocks.

How does Lipocine compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Citius Oncology currently has a consensus target price of $6.00, suggesting a potential upside of 650.09%. Lipocine has a consensus target price of $15.00, suggesting a potential upside of 635.29%. Given Citius Oncology's higher probable upside, research analysts plainly believe Citius Oncology is more favorable than Lipocine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Citius Oncology and Citius Oncology both had 1 articles in the media. Citius Oncology's average media sentiment score of 0.25 beat Lipocine's score of 0.00 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Citius Oncology has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Lipocine	-571.18%	-66.70%	-59.39%

Lipocine has higher revenue and earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Lipocine	$1.98M	8.49	-$9.63M	-$1.88	N/A

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 6.4% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Citius Oncology has a beta of 3.42, suggesting that its stock price is 242% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

Summary

Citius Oncology beats Lipocine on 9 of the 13 factors compared between the two stocks.

How does Lipocine compare to Pliant Therapeutics?

Lipocine (NASDAQ:LPCN) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Lipocine has higher revenue and earnings than Pliant Therapeutics. Lipocine is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	8.49	-$9.63M	-$1.88	N/A
Pliant Therapeutics	$1.58M	45.07	-$149.34M	-$1.84	N/A

Lipocine currently has a consensus price target of $15.00, suggesting a potential upside of 635.29%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 160.87%. Given Lipocine's stronger consensus rating and higher probable upside, research analysts plainly believe Lipocine is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

9.1% of Lipocine shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 6.4% of Lipocine shares are held by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lipocine and Lipocine both had 1 articles in the media. Lipocine's average media sentiment score of 0.00 equaled Pliant Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pliant Therapeutics has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Pliant Therapeutics' return on equity of -58.11% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Lipocine has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Summary

Pliant Therapeutics beats Lipocine on 10 of the 15 factors compared between the two stocks.

How does Lipocine compare to BioHarvest Sciences?

BioHarvest Sciences (NASDAQ:BHST) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

9.1% of Lipocine shares are held by institutional investors. 6.4% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Lipocine had 1 more articles in the media than BioHarvest Sciences. MarketBeat recorded 1 mentions for Lipocine and 0 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 0.00 equaled Lipocine'saverage media sentiment score.

Company	Overall Sentiment
BioHarvest Sciences	Neutral
Lipocine	Neutral

BioHarvest Sciences has a net margin of -32.54% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Lipocine	-571.18%	-66.70%	-59.39%

BioHarvest Sciences has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

Lipocine has lower revenue, but higher earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$34.51M	1.77	-$11.14M	-$0.59	N/A
Lipocine	$1.98M	8.49	-$9.63M	-$1.88	N/A

BioHarvest Sciences presently has a consensus target price of $10.00, indicating a potential upside of 220.51%. Lipocine has a consensus target price of $15.00, indicating a potential upside of 635.29%. Given Lipocine's stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Lipocine beats BioHarvest Sciences on 10 of the 16 factors compared between the two stocks.

How does Lipocine compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Seres Therapeutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 6.4% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Seres Therapeutics has higher earnings, but lower revenue than Lipocine. Seres Therapeutics is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	76.95	$5.70M	-$5.17	N/A
Lipocine	$1.98M	8.49	-$9.63M	-$1.88	N/A

In the previous week, Seres Therapeutics had 3 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for Seres Therapeutics and 1 mentions for Lipocine. Seres Therapeutics' average media sentiment score of 0.81 beat Lipocine's score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Seres Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 250.32%. Lipocine has a consensus target price of $15.00, indicating a potential upside of 635.29%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Seres Therapeutics has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Lipocine	-571.18%	-66.70%	-59.39%

Summary

Lipocine beats Seres Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Lipocine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LPCN vs. The Competition

Export

Metric	Lipocine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.90M	$2.96B	$6.49B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.57%
P/E Ratio	-1.09	12.28	20.24	21.95
Price / Sales	8.49	288.30	507.57	108.00
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	0.78	3.83	10.28	6.78
Net Income	-$9.63M	$75.85M	$3.57B	$337.51M
7 Day Performance	-10.53%	-4.52%	-1.43%	-2.72%
1 Month Performance	-13.92%	-5.85%	3.27%	1.87%
1 Year Performance	-35.03%	15.31%	23.37%	26.61%

Lipocine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LPCN Lipocine	3.4921 of 5 stars	$2.04 -0.5%	$15.00 +635.3%	-34.7%	$16.90M	$1.98M	N/A	10
XBIT XBiotech	0.3556 of 5 stars	$2.41 +1.3%	N/A	-18.3%	$73.48M	N/A	N/A	100	Positive News
CTOR Citius Oncology	2.0437 of 5 stars	$0.78 -1.2%	$6.00 +666.8%	-25.7%	$72.76M	$5.61M	N/A	N/A
PLRX Pliant Therapeutics	1.499 of 5 stars	$1.16 -3.3%	$3.00 +158.6%	-29.4%	$71.83M	N/A	N/A	90	Positive News
BHST BioHarvest Sciences	2.0952 of 5 stars	$3.62 -2.2%	$10.00 +176.2%	-54.2%	$71.02M	$34.51M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LPCN) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lipocine (LPCN) Competitors

LPCN vs. XBIT, CTOR, PLRX, BHST, and MCRB

How does Lipocine compare to XBiotech?

Summary

How does Lipocine compare to Citius Oncology?

Summary

How does Lipocine compare to Pliant Therapeutics?

Summary

How does Lipocine compare to BioHarvest Sciences?

Summary

How does Lipocine compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lipocine (LPCN) Competitors

LPCN vs. XBIT, CTOR, PLRX, BHST, and MCRB

How does Lipocine compare to XBiotech?

Which has more volatility & risk, XBIT or LPCN?

Which has better earnings & valuation, XBIT or LPCN?

Do institutionals and insiders hold more shares of XBIT or LPCN?

Does the media refer more to XBIT or LPCN?

Is XBIT or LPCN more profitable?

Do analysts rate XBIT or LPCN?

Summary

How does Lipocine compare to Citius Oncology?

Do analysts recommend CTOR or LPCN?

Does the media favor CTOR or LPCN?

Is CTOR or LPCN more profitable?

Which has better valuation and earnings, CTOR or LPCN?

Do insiders and institutionals hold more shares of CTOR or LPCN?

Which has more volatility & risk, CTOR or LPCN?

Summary

How does Lipocine compare to Pliant Therapeutics?

Which has better earnings and valuation, LPCN or PLRX?

Do analysts rate LPCN or PLRX?

Do insiders & institutionals have more ownership in LPCN or PLRX?

Does the media favor LPCN or PLRX?

Is LPCN or PLRX more profitable?

Which has more risk & volatility, LPCN or PLRX?

Summary

How does Lipocine compare to BioHarvest Sciences?

Do insiders and institutionals believe in BHST or LPCN?

Does the media refer more to BHST or LPCN?

Is BHST or LPCN more profitable?

Which has more risk & volatility, BHST or LPCN?

Which has stronger earnings & valuation, BHST or LPCN?

Do analysts prefer BHST or LPCN?

Summary

How does Lipocine compare to Seres Therapeutics?

Which has more risk and volatility, MCRB or LPCN?

Do insiders & institutionals believe in MCRB or LPCN?

Which has better valuation & earnings, MCRB or LPCN?

Does the media refer more to MCRB or LPCN?

Do analysts prefer MCRB or LPCN?

Is MCRB or LPCN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools